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Abstract. Brain deterioration resulting from “protein folding” diseases, such as the Alzheimer’s disease (AD), is one of the
leading causes of morbidity and mortality in the aging human population. Heat shock proteins (Hsps) constitute the major
cellular quality control system for proteins that mitigates the pathological burden of neurotoxic protein fibrils and aggregates.
However, the therapeutic effect of Hsps has not been tested in a relevant setting. Here we report the dramatic neuroprotective
effect of recombinant human Hsp70 in the bilateral olfactory bulbectomy model (OBX mice) and 5XFAD mouse models of
neurodegeneration. We show that intranasally-administered Hsp70 rapidly enters the afflicted brain regions and mitigates multiple
AD-like morphological and cognitive abnormalities observed in model animals. In particular, in both cases it normalizes the
density of neurons in the hippocampus and cortex which correlates with the diminished accumulation of amyloid- (A) peptide
and, in the case of 5XFAD mice, reduces A plaque formation. Consistently, Hsp70 treatment also protects spatial memory in
OBX and 5XFAD mice. These studies demonstrate that exogenous Hsp70 may be a practical therapeutic agent for treatment
of neurodegenerative diseases associated with abnormal protein biogenesis and cognitive disturbances, such as AD, for which
neuroprotective therapy is urgently needed.
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INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent neu-
rodegenerative pathology in the growing population of
elderly humans and leads eventually to dementia and
death. Despite tremendous efforts, no effective treat-
ment for AD is currently available. The severity of
cognitive impairment in patients with AD usually cor-
relates with the extent of the observed abnormality of
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neurons, including the quantity of neurofibrillary tan-
gles, the decrease in synaptic density, the enhanced
concentration of soluble amyloid- (A) oligomers,
and the amount of neurons that die by apoptosis [1–3].
Heat shock proteins (Hsps) have emerged as critical
regulators of neurodegenerative processes associated
with protein misfolding in the brains of AD patients
[4–6]. Various data suggest that Hsp70 and other
molecular chaperones function as a complex neuro-
protective system, which fails in the brains of AD
patients [5]. Indeed, the expression and functionality
of the inducible form of Hsp70 and other major Hsps
becomes compromised in aging brain tissue [6]. Yet
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the neuroprotective role of Hsp70 has been demon-
strated in several animal models of neurodegeneration
[7–10]. In a cellular model of AD, Hsp70 overexpres-
sion effectively protected neurons from intracellular
accumulation of A [6, 10]. Although a large body of
evidence attests to a neuroprotective role of chaper-
ones, there has been no direct demonstration that any
of them could either delay the progression of AD or
exert any therapeutic effect.
To investigate the potential therapeutic effect of
Hsps, we used two mouse models of AD-like neurode-
generation: olfactory bulbectomized mice (OBX) and
5XFAD transgenic mice [11, 12]. OBX animals exhibit
functional, morphological, and biochemical character-
istics similar to those described for AD patients [2, 17,
18], including severe memory loss [11, 13–16]. Simi-
lar to AD patients, OBX mice display a decreased use
of cerebral glucose [19] and an increased level of brain
amyloid- protein precursor (APP) and A [16, 20,
21]. In OBX guinea pigs, which have the A amino
acid sequence identical to that of the human ortho-
logue, intracellular accumulation of A in neurons of
the cortex and the formation of extracellular amyloid
plaques were observed [11]. Similar to AD patients,
OBX mice display a deficit of serotonin, acetylcholine,
and glutamatergic brain systems [22–24]. Most impor-
tantly, in contrast to many widely used transgenic mice
models of AD [25–27], OBX animals are characterized
by a substantial death of neurons in the hippocampus
and temporal cortex [16, 28, 29], i.e., the brain regions
most affected in AD individuals [30].
5XFAD mice represent a widely used conventional
model of AD-like neurodegeneration. In contrast to
OBX animals, they are characterized by a high level of
amyloid plaques that appear early in their lifespan in
different brain regions [12].
Recently, we have presented the results of complex
analysis of various pathological consequences of olfac-
tory bulbectomy in mice and the results of endogenous
Hsp70 levels measurements in the brains of OBX and
sham-operated (SO) mice that served as controls in dif-
ferent post-operation time periods [16]. We observed
a highly consistent inverse correlation between the
level of inducible Hsp70 and AD-like symptoms at
different stages of pathology development [16]. Fur-
thermore, it has been recently demonstrated that in
transgenic mice constitutively expressing Hsp70 in
various brain regions, AD-related phenotypes were
suppressed [31]. Since 2000, many studies using ani-
mal models of neurological diseases have shown that
intranasal administration of large-sized molecules can
produce beneficial effects (see [32] for review).
These findings prompted us to investigate a potential
pharmacological role of intranasally-injected exoge-
nous human Hsp70 in mouse models of AD. Our
results show that Hsp70 treatment is highly effective
in ameliorating all major manifestations of neurode-
generation developed in OBX and 5XFAD animals at
histological and cognitive levels.
MATERIALS AND METHODS
Animals
Adult males of NMRI mice and transgenic 5XFAD
mice were used in experiments. The animals were
maintained in their home cages in a climate-controlled
room (21–23°C) with a 12:12 h light-dark cycle
and had free access to water and food. 5XFAD
mice (TG6799) have been described previously [12].
These mice co-express the Swedish (K670N/M671L),
Florida (I716V) and London (V717I) mutations in
human APP(695), and M146L and L286V muta-
tions in PS1, with expression of both transgenes
driven by Thy1 promoter. Transgenic mice were
acquired from Jackson Laboratory and maintained
on a mixed SJL/C57Bl6. Mice were genotyped
by PCR analysis of DNA extracted from ears
biopsies. The transgenic cassette was detected
using primers 5’-AGGACTGACCACTCGACCAG-3’
and 5’-CGGGGGTCTAGTTCTGCAT-3’, yielding a
377 bp product.
Olfactory bulbectomy procedure
Four groups of NMRI mice aged to10 weeks (n = 55)
were employed in experiments: in two groups the olfac-
tory bulbs were removed (OBX mice) and the other
two groups underwent a sham operation (SO). Mice
were anaesthetized with Nembutal (40 mg/kg, i.p.) and
0.5% Novocaine for local anesthesia of the scalp. A
single burr hole (2 mm diameter) was drilled over the
olfactory bulbs (2 mm anterior to the bregma, 0 mm lat-
erally from the midline). Both the olfactory bulbs were
carefully aspirated through a blunt needle attached to
a water pump. The extent of the lesion was assessed
both visually and histologically at the end of the exper-
imental study. SO mice were treated similarly, except
that the olfactory bulbs were not removed. All proce-
dures involving animals were reviewed and approved
by the Animal Care and Use Committee of Branch
of Shemyakin & Ovchinnikov Institute of Bioorganic
Chemistry.
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Tissue preparation
Mice were anaesthetized with overdose Nembutal
(60 mg/kg, i/p) and perfused transcardially with 20 ml
of PBS (pH 7.4). Brains were rapidly removed and
divided into hemispheres. One hemisphere was frozen
on dry ice and stored at −80◦C. The other was fixed in
4% phosphate-buffered paraformaldehyde at 4◦C for
48 h before being stored in 30% sucrose. Hemibrains
were cut in the coronal plane at 20m sections on a
cryostat and stored in a glycol-based cryoprotectant at
−20◦C until histological analysis.
Histology and morphology
General histological methods were done as
described [16, 29]. A detailed description of all pro-
cedures is provided in the Supplementary Data.
Confocal microscopy
Sections of brains from mice with intranasal injec-
tion of human HSP70 labeled by Alexa Fluor 647
were inspected under a scanning confocal micro-
scope “Axioplan 2”. Sections were observed using
10x/0.3 NA or 20x/0.5 NA Plan-Neofluar or 63x/1.4
NA Plan-Apochromat objective on microscope Axio-
plan 2 equipped with a Zeiss LSM-510 META scan
head. HeNe laser was used to generate the 633 nm
line used for excitation, and pinholes were typically
set to 1–1.5 airy units. For Alexa Fluor 647, we col-
lected 3–9 images of non-overlapping fields of cells at
low power (total of 56 photomicrographs for analysis).
Additionally, we collected three images of nonoverlap-
ping fields of labeled cells at high power (total of 36
photomicrographs for analysis). High-power images
were collected from the olfactory bulb, the temporal
cortex, CA1, and CA3 areas of the hippocampus, the
locus coeruleus, the nucleus raphe dorsalis, and cere-
bellum. Images were exported and stored as TIFF files.
Treatments
Two weeks following bulbectomy or SO proce-
dures, mice were randomly divided into four groups:
two groups denoted as (SO + Hsp70) and (OBX +
Hsp70) were treated with Hsp70 (2g/mouse in 4l
intranasal injections) daily for 21 days. Intranasal
administration of Hsp70 has been carried out with the
help of a micropipette. A drop of solution was placed
just outside a nostril and was inhaled by an animal
without any stress in the process of normal breathing.
In the remaining two groups, denoted as SO and
OBX, animals were administered with 0.9% saline
(intranasal injection) during the same period and
the same volume. Hsp70 or saline were injected 1 h
before training and memory testing. In separate exper-
iments, we explored heat-denatured Hsp70 as a control.
5XFAD Tg+ and Tg− mice were divided into four
groups as well, at 2 months of age, and were treated for
1 month with the same dose of Hsp70 (2g/mouse in
4l intranasal injections) daily. Groups were denoted
as (Tg+), (Tg+ + Hsp70), (Tg−), and (Tg− + Hsp70).
Morris water maze tests were performed as
described [16]. The details of the procedure and maze
description are given in Supplementary Data.
Isolation and labeling of human recombinant
Hsp70
In our research we used human recombinant
Hsp70 expressed in army worm (Spodoptera) cells
or in E. coli. The original clone containing human
Hsp70 cDNA (pBlueScriptSK(+)-hsp70) (a generous
gift of Dr. R. Morimoto, Northwestern University,
Evanston, USA) was subcloned into the donor plas-
mid pFastBacHTb-hsp70 under polyhedrin promoter.
The plasmid was subsequently used in Bac-to Bac sys-
tem (Invitrogen) in order to express human Hsp70.
Recombinant protein contained six His at its N-end
which enables its isolation from the cell extracts using
Ni-NTA resin columns according to the manufac-
turer’s instructions (QUIAGEN, Ni-NTA Superflow
BioRobot Hand Book).
The purity of Hsp70 preparations from E.coli
and Spodoptera cells was confirmed by PAGE-
electrophoresis followed by staining with Coomassie
Blue and immunoblotting using monoclonal 3B5
anti-Hsp70 and N69 anti-Hsc70 antibodies. Protein
concentration was measured according to Bradford’s
protocol.
For localization experiments, human recombinant
Hsp70 was conjugated with Alexa Fluor 647 dye (Invit-
rogen, Carlsbad, USA) according to instructions of
manufacturer.
RESULTS
Hsp70 rapidly enters speciﬁc brain regions after
intranasal administration to mice
Although previously, using various mammalian cell
cultures, it was shown that labeled exogenous Hsp70
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Fig. 1. Localization of exogenous Hsp70 in different brain regions of control mice after intranasal administration. The images show fluorescently
labeled with the Alexafluor 647 dye Hsp70 (red) in the brain sections of NMRI mice 3 h after intranasal injection. Hsp70 is distributed non-
randomly and concentrated in a few brain structures. Photos show its localization in the olfactory bulbs (A, B), areas of the hippocampus (C,
D), in the n. raphe dorsalis (E, F), and in cells of the cerebellum (G, H). In most cases Hsp70 has an intracellular localization (B, D, F, H)
and is restricted to the perinuclear zone (indicated by arrow in D and H). Control mice treated with unlabeled Hsp70 do not exhibit any brain
fluorescence (I). Scale bars: A = 300m; B, D, F, H, I = 20m; C, E, G = 100m.
is able to penetrate cells [7] and localizes in neu-
rons of the rat brain after intraventricular injection
[33], it was necessary to directly prove that after
intranasal administration, recombinant Hsp70 was
able to enter the brain and find its way to spe-
cific brain structures. To trace exogenous Hsp70 and
determine whether it could indeed reach the brain to
exert its therapeutic effect, we monitored the distri-
bution of Alexa-labeled Hsp70 in specific areas of
the brain by confocal microscopy. Three hours after
intranasal administration fluorescently-labeled Hsp70
was readily detected in the olfactory bulbs, neocortex,
hippocampus, n.raphe dorsalis, locus coeruleus, and
cerebellum in intact (non-operated) mice (Fig. 1). In
most cases, it showed intracellular localization which
was concentrated in the perinuclear zone (e.g., Fig. 1D,
H). In similarly treated OBX mice, labeled Hsp70 was
observed in essentially the same brain regions, how-
ever, the protein formed aggregates more randomly
spaced throughout the cytoplasm (Supplementary Fig-
ure 1). The fluorescent material was absent in the brain
slices of mice following intranasal administration of
unlabeled Hsp70 or control naive NMRI mice (Fig. 1I).
Therefore, intranasally injected Hsp70 is apparently
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Fig. 2. Hsp70 improves memory in OBX and 5XFAD mice. The protective effects of sub-chronic intranasal administration of exogenous Hsp70
on spatial memory of OBX (A, B) and 5XFAD (C) mice. Results are presented as post-hoc data of ANOVA analysis. Hatched bars represent
time (in seconds) spent by different groups of mice in the target sectors during probe trial (mean ± SEM); other bars represent time spent in
indifferent sectors. Probe trials with independent groups of OBX and SO animals were performed four weeks after bulbectomy immediately after
Hsp70 treatment (left panel-A) or eight months after bulbectomy and seven months following Hsp70 treatment (right panel-B). (C) The effect
of Hsp70 administration on spatial memory of 5XFAD mice (3 months age). Asterisks indicate significant differences (*p < 0.05; **p < 0.01;
***p < 0.001) in comparison with the target quadrant.
able to enter the brain rapidly both in OBX and con-
trol mice and be transported within neurons of brain
regions, including specific areas where neurodegener-
ation predominantly develops in AD patients.
Exogenous Hsp70 protects spatial memory in OBX
and 5XFAD mice
The results described above provided a rational
for the use of intranasally-injected exogenous Hsp70
as a potential protective agent to ameliorate the
severe memory impairment observed in OBX and
5XFAD mice. Highly pure human Hsp70 was admin-
istered intranasally for a 21-day period starting two
weeks after the bulbectomy (n = 13) or sham operation
(n = 13). In the case of 5XFAD mice, the two month
old animals were similarly treated with Hsp70 for one
month. The training trials in the Morris water maze
were performed either four weeks or eight months after
the olfactory bulb ablation. As illustrated by the learn-
ing curves (Supplementary Figure 2A-C), all groups
improved their performance, i.e., reduced the latent
period of finding the invisible platform, with training.
OBX mice found the save platform slower than SO
mice (p < 0.05) only on days 1 and 2 of training. How-
ever, there was no statistical difference in the learning
abilities between any groups over the 5-day training.
It is important that the latent periods in experimen-
tal groups did not significantly differ on the last day
of the training in both testing periods (Supplementary
Figure 2).
Figure 2 illustrates the effect of Hsp70 on spatial
memory as judged by the time spent in the target sector
of Morris water maze in comparison to other indif-
ferent sectors. It is evident that untreated OBX and
5XFAD mice had severely impaired spatial memory.
In contrast, OBX+Hsp70 and 5XFAD+Hsp70 mice
displayed a significant preference for the target sec-
tor as determined by ANOVA and post-hoc analysis
of their occupancy time (Figs. 2A-C and Supple-
mentary Table 1). While untreated 5XFAD and OBX
animals in both periods of testing (one or eight months
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Table 1
Effect of Hsp70 intranasal administration on morphology of the temporal cortex and areas of the hippocampus
Brain areas Groups Kinds of neuronal pathology observed in % Normal
neurons in %
Pyknosis Karyolysis Cytolysis Vacuolization
Temporal cortex SO 9.9 ± 0.68 3.1 ± 0.23 5.9 ± 0.49 2.7 ± 0.38 75.9 ± 1.1
SO+Hsp70 11.28 ± 0.43 4.2 ± 0.37 14.6 ± 0.45*** 2.9 ± 0.41 67.0 ± 0.91***
OBX 18.5 ± 0.66*** 5.7 ± 0.26*** 18.6 ± 0.51*** 2.9 ± 0.28 53.6 ± 1.0***
OBX+Hsp70 9.4 ± 0.68◦◦◦ 3.6 ± 0.43◦◦ 19.2 ± 0.82*** 2.3 ± 0.28 65.7 ± 1.5*** ◦◦◦
CA1 SO 6.3 ± 0.66 2.9 ± 0.26 5.9 ± 0.46 2.2 ± 0.26 82.6 ± 1.08
SO+Hsp70 7.4 ± 0.55 4.2 ± 0.33*** 10.3 ± 0.59 2.4 ± 0.29 75.7 ± 0.95***
OBX 15.9 ± 0.69*** 5.4 ± 0,31*** 17.1 ± 0.61*** 2.7 ± 0.24 59.0 ± 0.87***
OBX+Hsp70 6.5 ± 0.33◦◦◦ 4.2 ± 0.38** ◦ 19.1 ± 0.89*** ◦ 1.5 ± 0.21◦◦◦ 68.9 ± 1.19*** ◦◦◦
CA3 SO 4.6 ± 0.43 2.5 ± 0.23 5.9 ± 0.4 1.2 ± 0.16 85.8 ± 0.89
SO+Hsp70 8.6 ± 0.53** 3.1 ± 0.21*** 16.9 ± 0.44*** 1.8 ± 0.32* 69.6 ± 0.89***
OBX 16.7 ± 0.63*** 5.2 ± 0.33*** 21.1 ± 0.58*** 2.6 ± 0.2*** 54.0 ± 0.74***
OBX+Hsp70 6.6 ± 0.4** ◦◦◦ 5.2 ± 0.37*** 18.5 ± 0.65***◦◦ 1.7 ± 0.23◦◦ 67.4 ± 1.02*** ◦◦◦
Data are given as mean ± SEM. Comparison between the groups were performed separately for the temporal cortex and both areas of the
hippocampus with two-tail Student’s t test to compare replicate means with special emphasis on bulbectomy-induced changes (***p < 0.001)
and effects of Hsp70 treatment in OBX mice (◦◦◦p < 0.001).
after olfactory bulb ablation) exhibited impairment of
spatial memory and could not recognize the target sec-
tor, the Hsp70 treatment of the model mice not only
prevented memory deterioration shortly after Hsp70
treatment (e.g., one month following the operation) but
also ameliorates memory deficit manifestations in the
remote period following the operation. That is OBX
mice studied seven months after Hsp70 treatment also
demonstrate significant memory restoration probably
resulted from Hsp70 pretreatment at the early stage of
the pathology development.
A control set of experiments conducted prior to the
training trials demonstrated that bulbectomy per se as
well as Hsp70 administration did not induce motor or
visual impairments that could affect the results of the
memory test. There were no differences in tests with
a visible unhidden platform in the Morris water maze
between untreated 5XFAD mice and Hsp70 treated ani-
mals. We therefore conclude that subchronic intranasal
injection of Hsp70 protected spatial memory in both
OBX and 5XFAD animals.
To further characterize the protective role of Hsp70
at the cellular level, we performed detailed analysis of
neuronal abnormalities in OBX mice treated by Hsp70
and in untreated control groups.
Hsp70 treatment reduces the accumulation of Aβ
in the brains of OBX and 5XFAD mice
An abnormally high accumulation of A peptides in
afflicted regions of the brain is a biochemical hallmark
of AD patients and also a prominent characteristic of
OBX and 5XFAD mice [12, 16]. To examine the effect
of Hsp70 treatment on this AD-specific marker, we
measured the level of A in an extract of the cortex
and hippocampus by using an Invitrogen ELISA mouse
beta amyloid (1–40) kit (Invitrogen, Camarillo, CA).
We decided to compare the level of “1–40” peptide
in both experimental systems because “1–42” peptide
for some reason is not detected in OBX mice. The total
amount of A (pooled soluble and insoluble fractions)
in the untreated groups of OBX and 5XFAD mice was
significantly higher than that in the control and groups
subjected to Hsp70 treatment (p < 0.001) (Fig. 3A, B).
Importantly, Hsp70 treatment per se did not affect the
basal level of A in the control groups. Thus, sub-
chronic Hsp70 treatment effectively protects the brains
of mice from the accumulation of potentially toxic A
peptide in both animal models of AD.
It is known that 5XFAD mice develop characteristic
A plaques in 2-3 months after birth [12]. Intranasal
Hsp70 administration for 1 month dramatically dimin-
ished the plaque density in the neocortex and CA1
region of the hippocampus in Hsp70-treated 5XFAD
mice (Fig. 3C). Examples of typical patterns of plaque
distribution in the neocortex in control and experimen-
tal animals are depicted in Fig. 3D.
Hsp70 treatment improves neuronal survival and
morphology in OBX mice
Despite the pronounced accumulation of A, OBX
mice do not develop plaques, but do demonstrate death
of neurons in the brain. Therefore, we explored the
effect of Hsp70 on state of neurons in the cortex and the
hippocampus of OBX animals. To investigate whether
the dramatic protective effect of Hsp70 on cogni-
tion occurred in parallel with the mitigation of other
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Fig. 3. Exogenous Hsp70 protects the brain of OBX and 5XFAD mice from A accumulation and amyloid plaque formation. A, B) OBX and
5XFAD mice treated with intranasal Hsp70 are characterized by decreased level of A in the brain. Bars indicate the level of A peptides
(mean ± SEM) determined by ELISA in the brain tissue (cortex + hippocampus) in the groups of OBX and 5XFAD mice (n = 6–11 animals
per group). Differences between the levels of A in the groups were determined by using the two-tailed Student’s t-test. C) The density of A
plaques in Hsp70 treated and untreated 5XFAD mice. D) The representative microphotohraphs of neocortical slices in non transgenic mouse
and 5XFAD mice exhibiting A plaques in animals treated with Hsp70 and in control.
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AD-like symptoms in OBX mice, we investigated the
morphology of neurons and their density in the dorsal
hippocampus (CA1 and CA3 areas) and temporal cor-
tex because these regions are central to learning and
memory and are the most damaged in AD patients.
Importantly, SO mice did not display any significant
changes in the form, size, or structural organization
of neural cells 5 weeks after the operation (Table 1).
Most of the neurons in this group exhibited normal phe-
notypic characteristics, evenly distributed tigroid and
light colored, centrally positioned nuclei with easily
distinguishable nucleoli. In contrast, most neurons of
the OBX animals displayed fundamental morphologi-
cal changes in the regions examined. The anomalies
included pyknosis, karyolysis, cytolysis, and vac-
uolization (Table 1, Supplementary Materials and
Methods). Characteristically, the proportion of patho-
logic neurons decreased drastically in OBX+Hsp70
animals. The data demonstrate that the Hsp70 treat-
ment prevents the development of pathology in neurons
of the OBX group. Consistent with the protection
of cells, Hsp70 significantly improved neuronal sur-
vival in OBX mice. Quantitative analysis (Table 1)
revealed that the Hsp70-treated OBX mice had signif-
icantly more intact neurons in the temporal cortex and
hippocampus. The results presented in Table 1 demon-
strate that neuronal density in the C1 and C3 regions
of the hippocampus in OBX+Hsp70 group is similar
to that of control SO mice. Therefore, Hsp70 treatment
of OBX mice protects neurons from deterioration and
death in brain areas most affected in AD patients.
DISCUSSION
Several observations demonstrate that chaperones
belonging to Hsp70 family can ameliorate cellular
toxicity of aberrantly folded proteins extant in AD,
Parkinson’s disease, amyotrophic lateral sclerosis, and
polyQ-diseases [4, 34, 35], suggesting that treatment
with Hsp70 could potentially be therapeutic for these
devastating neurodegenerative diseases. It is of note
that an understanding of the role played by stress-
related proteins has developed more slowly for AD,
mostly due to the lack of animal models that accurately
replicate the major characteristics of the human dis-
ease. Our results reported herein provide the first direct
experimental evidence supporting this hypothesis.
At the first stage of our research, we demonstrated
that exogenous Hsp70 promptly enters the mammalian
brain and its neuronal cells after intranasal adminis-
tration, both in OBX and intact control mice. It has
been recently shown that direct delivery of various
therapeutics including proteins from the nasal cavity
into the central nervous system somehow bypasses the
blood-brain barrier and provides an attractive alter-
native to invasive methods of drug administration.
Precise mechanisms providing such transport are not
known and may involve neuron terminals, bulk flow
and diffusion within perineuronal channels, perivascu-
lar spaces, or lymphatic channels directly connected
to brain tissue [36]. Whatever the mechanism, it is
likely to require an as yet unidentified cellular trans-
port machinery specific to Hsp70. It is noteworthy that
Hsp70 injected directly into the brain of rats (intrac-
erebroventicularly) is localized in essentially the same
brain regions [33]. It has been also shown by this group
that fluorescently-labeled Hsp70 is seen in particular
neuronal terminals and co-localized in these regions
with NMDA receptors, synaptophysin, and the GABA-
synthesizing enzyme [33].
Furthermore, in two complementary models of AD,
namely in OBX and 5XFAD mice, we showed that
the intranasal administration of full-length recombi-
nant human Hsp70 drastically alleviates all symptoms,
including memory loss, neuronal death, cellular aber-
rations, and accumulation of the A peptide. It is
noteworthy that major symptoms observed in OBX
mice are similar to those of the more conventional
transgenic 5XFAD model of AD-like degeneration. In
both models, the memory improvement after Hsp70-
treatment correlates with the decrease in A levels,
and in the case of 5XFAD mice, with the diminished
density of amyloid plaques. Interestingly, in contrast to
OBX mice, OBX guinea pigs, which naturally express
A that is identical to its human counterpart, do gen-
erate plaques [11]. The extent of cognitive impairment
and neuronal loss, however, is similar between OBX
mice and OBX guinea pigs, suggesting that plaque
formation per se is not a major cytotoxic factor, but
rather a phenotypic manifestation of A misfolding,
which varies depending on its precise sequence. It is
likely that the level of soluble A and its aggregates
are mostly responsible for the cytotoxicity [37]. Thus
it was demonstrated that intracellular accumulation of
A is an early event in neuronal dysfunction [38] and
cytosolic A has been shown to be highly cytotoxic
to primary neurons [39]. Hsp70 may thus form com-
plexes with soluble A oligomers and suppress their
toxicity leading to the observed neuronal protection.
Furthermore Hsp70 may deliver the aberrant peptides
to the protein degradation machinery such as the pro-
teasome, preventing the increase in its content [40].
Remarkably, the therapeutic effect of Hsp70 in OBX
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mice was induced by a single course of treatment with
a small dose of protein (see Methods), and in the case
of OBX mice lasted for at least eight months (the extent
of the experiment). It is clear that such a long-lasting
effect of exogenous Hsp70 cannot be readily explained
by its direct chaperone activity against misfolded AD
proteins, or by indirect effects, such as the suppression
of apoptosis and Hsp70-mediated autophagy [41]. In
this regard, recent findings that exogenous Hsp70 could
stimulate the innate immune response and significantly
reduce the level of reactive oxygen species may sug-
gest clues as to the mechanisms responsible for the
observed phenomena [42–44].
It is of note that there are other agents besides Hsp70
(e.g., phytic acid) that provide protection against A
in cellular and mouse models by attenuating levels of
reactive oxygen species production [45].
On the other hand, Hsp70 treatment produces a
clear cut adverse effect on the SO mice, i.e., in the
CA3 region the level of normal neurons in SO group
drops from 87 to 70% (Table 1). Therefore, the treat-
ment apparently results in neuron protection only in
the case of neuropathology (5XFAD and OBX mice).
Along these lines, it has been previously demon-
strated that in Drosophila constitutive expression of
Hsp70 in otherwise normal flies has various deleterious
effects [46, 47].
It is noteworthy that the use of intranasal adminis-
tration of recombinant Hsp70 is not the first attempt
to treat AD-like symptoms. Thus, intranasal admin-
istration of insulin was found effective to modulate
verbal memory and plasma A in memory-impaired
older adults and in other model systems [48, 49].
Taken together, our findings not only establish
exogenous Hsp70 as a potentially practical phar-
macological agent for the treatment of various
neurodegenerative diseases, but also reveal novel func-
tions of mammalian Hsp70. It is necessary to mention
that Hsp70 is able to form complexes with tau and
be involved in its degradation process [50], therefore,
Hsp70 treatment may be effective not only for AD but
other neurodegenerative diseases with tauopathies.
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